Kamada (NASDAQ:KMDA) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.
Several other equities analysts have also recently issued reports on the stock. TheStreet upgraded shares of Kamada from a “c” rating to a “b” rating in a research note on Friday, February 9th. HC Wainwright reiterated a “buy” rating on shares of Kamada in a research note on Thursday, February 8th. Chardan Capital started coverage on shares of Kamada in a research note on Friday, February 2nd. They issued a “buy” rating and a $7.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Kamada from a “sell” rating to a “hold” rating in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $7.00.
Shares of Kamada (NASDAQ KMDA) opened at $5.20 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.58 and a current ratio of 3.30. Kamada has a 12 month low of $3.75 and a 12 month high of $8.61. The company has a market cap of $209.37, a P/E ratio of 28.89 and a beta of 1.12.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Meitav Dash Investments Ltd. purchased a new stake in Kamada in the 4th quarter worth $3,512,000. Vanguard Group Inc. increased its holdings in Kamada by 6.5% in the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after acquiring an additional 28,382 shares in the last quarter. Analyst IMS Investment Management Services Ltd. increased its holdings in Kamada by 125.5% in the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 50,000 shares in the last quarter. ARK Investment Management LLC purchased a new stake in Kamada in the 4th quarter worth $251,000. Finally, Worth Venture Partners LLC purchased a new stake in Kamada in the 3rd quarter worth $246,000. Hedge funds and other institutional investors own 9.14% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ValuEngine Lowers Kamada (KMDA) to Sell” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3258418/valuengine-lowers-kamada-kmda-to-sell.html.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.